Curis, Inc. (CRIS) Announces Investigational New Drug Application Filing By Roche (RHHBY) To Initiate A Phase 2 Study Of Erivedge® (Vismodegib) In Idiopathic Pulmonary Fibrosis
6/23/2014 7:47:43 AM
LEXINGTON, Mass., June 23, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today announced that Roche has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate a multicenter, Phase 2 clinical study of Erivedge® (vismodegib) in patients with idiopathic pulmonary fibrosis (IPF), a chronic, debilitating lung disease. Roche and Genentech, a member of the Roche Group, develop and commercialize Erivedge under a collaboration agreement with Curis.
Help employers find you! Check out all the jobs and post your resume.
comments powered by